The molecular mechanisms that direct transcription of the gene encoding the transcription factor Foxp3 in CD4 + T cells remain ill-defined. We show here that deletion of the DNA-binding inhibitor Id3 resulted in the defective generation of Foxp3 + regulatory T cells (T reg cells). We identify two transforming growth factor-1 (TGF-1)-dependent mechanisms that were vital for activation of Foxp3 transcription and were defective in Id3 −/− CD4 + T cells. Enhanced binding of the transcription factor E2A to the Foxp3 promoter promoted Foxp3 transcription. Id3 was required for relief of inhibition by the transcription factor GATA-3 at the Foxp3 promoter. Furthermore, Id3 −/− T cells showed greater differentiation into the T H 17 subset of helper T cells in vitro and in a mouse asthma model. Therefore, a network of factors acts in a TGF--dependent manner to control Foxp3 expression and inhibit the development of T H 17 cells.
A r t i c l e s Regulatory T cells (T reg cells) that express the transcription factor Foxp3 are instrumental in the induction and maintenance of peripheral immune tolerance and the regulation of tumor immunity and infection [1] [2] [3] [4] [5] [6] [7] [8] . The differentiation of Foxp3 + T reg cells requires transforming growth factor-β (TGF-β) signaling [9] [10] [11] [12] [13] ; however, the molecular pathways that transduce this signal remain largely unknown. The TGF-β receptor-regulated adaptor molecules Smad2 and Smad3 and the common Smad protein Smad4 are involved in Foxp3 induction [14] [15] [16] . However, the Foxp3 promoter lacks Smad-binding sequences. In addition, the time lag between the activation of Smad2 or Smad3 (within minutes) and Foxp3 mRNA expression (over 12 hours) after stimulation with TGF-β1 suggests that there are intermediate factors between the TGF-β1mediated Smad signaling and Foxp3 transcription. Thus, understanding this is not only essential for understanding the generation of T reg cells but also important for the treatment of autoimmune diseases, infection and cancer 17 , especially given the reciprocal differentiation of TGF-β1-induced Foxp3 + T reg cells and interleukin 17 (IL-17)-producing helper T cells (T H 17 cells) [18] [19] [20] [21] [22] [23] .
Here we here show that the DNA-binding inhibitor Id3, a transcription factor involved in T cell development 24, 25 , growth inhibition of a B cell progenitors 26 and protection of mice against autoimmunelike Sjögren's syndrome 27 , regulated the TGF-β1-mediated reciprocal differentiation of T reg cells and T H 17 cells in mice. Deletion of Id3 blocked the TGF-β1-induced generation of Foxp3 + T reg cells. This was attributed to a failure to enrich binding of the transcription factor E2A and an inability to suppress binding of the transcription factor GATA-3 at the Foxp3 promoter in Id3 −/− T cells. These Id3 −/− T cells showed more differentiation into T H 17 cells in vitro and in vivo. Id3-dependent reciprocal regulation of T reg cells and T H 17 differentiation also occurred in an experimental model of house dust mite (HDM)induced allergic asthma in mice.
RESULTS
Fewer CD4 + Foxp3 + T reg cells in Id3 −/− mice Id3 −/− mice have been shown to develop a T cell-dependent autoimmune-like Sjögren's syndrome 27 ; we therefore reasoned that these mice might have a defect in the generation and/or function of CD4 + Foxp3 + T reg cells. Young Id3 −/− mice (3 weeks old) had a significantly lower frequency and absolute number of CD4 + Foxp3 + T reg cells in the spleen (Fig. 1a-d and Supplementary Fig. 1a ) and peripheral lymph nodes (data not shown) than did wild-type C57BL/6 mice. These young Id3 −/− mice also had fewer CD4 + Foxp3 + thymocytes ( Fig. 1a-d) .
Helios has been used as a marker to distinguish natural T reg cells from induced T reg cells 28 ; we observed that both Foxp3 + Helios + and Foxp3 + Helios − T reg cells were less abundant in Id3 −/− mice (Fig. 1b) . Therefore, in terms of Helios expression, both natural T reg cells and induced T reg cells are affected by the absence of Id3.
In contrast to the lower frequency and number of T reg cells in young Id3 −/− mice, the frequency of CD4 + Foxp3 + T reg cells in the spleen (Supplementary Fig. 1a) , lymph nodes and thymus (data not shown) of older Id3 −/− mice was gradually restored by 6-7 weeks of age and became even greater after 3-4 months. The recovery of T reg cells in older Id3 −/− mice was mainly due to expansion of the T reg cell population, as there were substantially more Ki67 + (dividing) cells among Id3 −/− T reg cells than among wild-type T reg cells ex vivo (Supplementary Fig. 1 ). Even in young (3- week-old) Id3 −/− mice, there was already a much greater frequency of Ki67 + cells among T reg cells than in wild-type mice (Supplementary Fig. 1) , despite the significantly fewer T reg cells in these young Id3 −/− mice ( Fig. 1a-d) .
Despite the recovery and even greater frequency of Foxp3 + T reg cells in older Id3 −/− mice, old Id3 −/− mice showed signs of T cell activation and inflammation 27 (Supplementary Fig. 1e ). This suggests that the initial deficiency in Foxp3 + T reg cells in the neonatal Id3 −/− mice resulted in dysregulated activation that affected the homeostasis of T cells in Id3 −/− mice. In addition, the suppressive function of Id3 −/− CD4 + CD25 + T reg cells was also compromised in in vitro coculture assays ( Fig. 1e and Supplementary Fig. 2) , whether the CD4 + CD25 − T responder cells being suppressed were wild-type ( Fig. 1e) or Id3 −/− (Supplementary Fig. 2a ). However, the expression of Foxp3 and other T reg cell-associated molecules such as CD25, CTLA-4 and GITR was unaltered in the Id3 −/− mice (data not shown). T reg cells from young Id3 −/− mice (3-5 weeks old; Fig. 1e and Supplementary  Fig. 2 ) or older Id3 −/− mice (4-6 months old; data not shown) showed compromised suppressive activity.
Next we generated mixed-bone marrow chimeras to further confirm the function of Id3 in the generation of CD4 + Foxp3 + T reg cells. We injected a mixture of C57BL/6 (CD45.1 + ) bone marrow and Id3 −/− (CD45.2 + ) bone marrow or a mixture of C57BL/6 (CD45.1 + ) bone marrow and wild-type (CD45.2 + ) bone marrow into sublethally irradiated recipient mice deficient in recombination-activating gene 1 (Rag1 −/− ). Both spleen and thymus reconstituted with Id3 −/− (CD45.2 + ) bone marrow contained fewer CD4 + Foxp3 + T reg cells than did those transplanted with wild-type (CD45.2 + ) bone marrow ( Fig. 1f-h) .
Similar to results obtained with intact Id3 −/− mice ( Fig. 1b) , both Foxp3 + Helios + and Foxp3 + Helios − T reg cells were less abundant in mice reconstituted with Id3 −/− bone marrow (Fig. 1f) . The deletion of Id3 therefore resulted in a deficiency in Foxp3 + T reg cells.
Id3 is required for TGF-1-induced Foxp3 expression
Next we determined whether Id3 deficiency affected the generation of Foxp3 + T reg cells in vitro. We cultured peripheral naive CD4 + CD25 − Foxp3 − T cells with CD3-and CD28-specific antibodies in the presence of TGF-β1 to induce Foxp3 + T reg cells 9 . TGF-β1 induced much less Foxp3 mRNA and Foxp3 protein in naive Id3 −/− CD4 + CD25 − T cells than in naive wild-type CD4 + CD25 − T cells ( Fig. 2a-c ) over a range of TGF-β1 concentrations, although the defect was partially reversed with high doses of TGF-β1 ( Supplementary  Fig. 3 ). The addition of exogenous IL-2 did not correct the defect (Fig. 2d) , which eliminated the possibility of a lack of IL-2 as the cause. The inclusion of retinoic acid in the cultures resulted in an only slightly higher percentage of Id3 −/− Foxp3 + T cells, whereas it produced the reported synergistic effect on TGF-β1-dependent Foxp3 + T reg differentiation of wild-type CD4 + T cells 29 (Fig. 2e) . Analysis of proximal Smad activation downstream of TGF-β1 signaling showed there was no substantial difference between Id3 −/− and wild-type CD4 + T cells in TGF-β receptor-activated phosphorylation of Smad2 and Smad3 (assessed as phosphorylated Smad2) after TGF-β1 treatment (Supplementary Fig. 4a ). Smad7, an inhibitory Smad that antagonizes Smad2-and Smad3-mediated TGF-β signaling 30 , was less abundant in Id3 −/− CD4 + T cells than in wild-type CD4 + T cells after TGF-β1 A r t i c l e s treatment ( Supplementary Fig. 4b ), which ruled out the possibility of Smad7 as a factor causing the diminished induction of Foxp3 in Id3 −/− cells. Id3 is therefore a critical component of TGF-β1-mediated generation of Foxp3 + T reg cells, but it probably functions downstream of signal pathways mediated by phosphorylated Smad2 and Smad3.
E2A enrichment at the Foxp3 promoter activates Foxp3
We next studied the molecular mechanisms by which Id3 is involved in the TGF-β1-induced generation of Foxp3 + T reg cells. Freshly isolated CD4 + CD25 + T reg cells from the spleen of wild-type mice had more Id3 mRNA and Id3 protein ( Supplementary Fig. 5a ,b) than did CD4 + CD25 − T cells. We then investigated whether TGF-β signaling affected Id3 expression in naive CD4 + T cells after stimulation of the T cell antigen receptor (TCR). Treatment with TGF-β1 resulted in more Id3 mRNA during the first 1-2 h than did stimulation of the TCR alone ( Supplementary Fig. 5c ), consistent with findings obtained with B cells 26 . However, by 12-24 h, TGF-β1-treated T cells had less Id3 mRNA than did T cells without TGF-β1 treatment ( Supplementary  Fig. 5c ). We further verified a role for TGF-β1 in the regulation of Id3 expression in mice with T cell-specific conditional deletion of TGFβ receptor I (with deletion of loxP-flanked (floxed) alleles encoding TGF-β receptor I (Tgfbr1 f/f ) mediated by Cre recombinase driven by the Cd4 promoter; Tgfbr1 f/f Cd4-Cre + mice) 12 , as CD4 + CD25 − T cells from these mice showed no difference in Id3 expression with or without TGF-β1 (data not shown). The regulation of Id3 by TGF-β1 required Smad3 and/or Smad4, as CD4 + CD25 − T cells either singly deficient in Smad3 (Smad3 −/− ) ( Supplementary Fig. 5d ) or doubly deficient in Smad3 and Smad4 (from Smad3 −/− Smad4 f/f Lck-Cre + mice, in which deletion of Smad4 f/f is mediated by Cre driven by the Lck promoter; data not shown) lost the aforementioned biphasic effects induced by TGF-β1. Thus, T reg cells have higher expression of Id3 and TGF-β1 regulates Id3 expression in naive CD4 + T cells in a time-dependent manner, with a transient increase during the first 2 h, followed by considerable downregulation by 12-24 h.
Id3 lacks the basic region needed for DNA binding but retains the functional dimerization domain and therefore is regarded as an inhibitor of the binding of E2A to its target genes through the formation of inactive heterodimers 24 . We therefore hypothesized that TGF-β1 might influence the binding of E2A to the Foxp3 promoter and thereby regulate gene transcription. E2A proteins (E47 and E12) have a DNAbinding domain and bind the CANNTG (where 'N' indicates any nucleotide; E-box) DNA motif as protein dimers to regulate gene transcription during the development of both T cells and B cells 24 . We first analyzed Foxp3 with the help of Genomatix Matinspector software and found that the sequence between −1.1 kb and +1.1 kb relative to the transcription initiation site (+1), contained many E-box elements with the canonical nucleotide sequence CANNTG, which are expected to bind members of the E-protein family of transcription factors [31] [32] [33] [34] (Fig. 3a) . Using naive CD4 + CD25 − T cells isolated from the spleens of wild-type mice, we analyzed whether TGF-β1 influenced the binding of E2A to the Foxp3 promoter. We treated CD4 + CD25 − T cells overnight with CD3-and CD28-specific antibodies and TGF-β1 and assessed binding of E2A to the Foxp3 promoter by chromatin immunoprecipitation (ChIP)-coupled quantitative PCR. For this we used an antibody to E47, a major component of the E2A protein 24 , to precipitate chromatin from CD4 + CD25 − T cells, followed by quantitative PCR analysis of the precipitated DNA. To determine where E2A binds to Foxp3, we analyzed the following three different regions of Foxp3: the 5′ promoter region (amplicon 1; position −995 to position −798); the proximal promoter plus a region consisting of the untranslated 5′ mRNA (amplicon 2; position +327 to position +513); and the region located next to the enhancer containing the Smad-binding domain (amplicon 3; position +2335 to position +2532) 15 (Fig. 3a) . We observed more binding of E2A to the regulatory region of Foxp3 comprising the proximal promoter and its untranslated 5′ mRNA region (positions +327 to +513; Fig. 3b ). We then quantitatively compared the binding of E2A to this region in Foxp3 in T cells with stimulation of the TCR alone or with TCR stimulation plus treatment with TGF-β1 and found that TGF-β1 significantly enhanced the binding of E2A to the promoter relative to binding in the control condition without TGF-β1 treatment ( Fig. 3c) . TGF-β1-driven enhancement of the binding of E2A to the Foxp3 promoter occurred 12-24 h after TGF-β1 stimulation, which correlated with the time of Foxp3 mRNA expression (>12 h) detected in TGF-β1-treated T cells (data not shown). This enrichment of E2A was probably not due to the change in protein amounts, as neither treatment substantially affected the expression of whole E2A protein ( Supplementary Fig. 6a ). More E2A binding was associated with binding of TBP (TATA-binding protein), a marker of active transcription, in the Foxp3 promoter ( Fig. 3d) , which suggested that both factors were recruited to this Foxp3-regulatory region. We confirmed the essential role of TGF-β1 signaling in promoting binding of E2A to the Foxp3 promoter by using Tgfbr1 f/f Cd4-Cre + CD4 + CD25 − T cells, which lack TGF-β signaling. There was no upregulation of E2A binding in response to TGF-β1 treatment ( Supplementary Fig. 6b ).
In addition to TGF-β1-treated naive CD4 + T cells, freshly isolated CD4 + CD25 + T reg cells from wild-type spleen also showed enrichment in E2A at the Foxp3 promoter relative to the binding in CD4 + CD25 − T cells ( Fig. 3e) . These data collectively support the idea of a positive role for E2A in the activation of Foxp3 transcription in response to TGF-β1 treatment, which can be explained by the direct binding of E2A to the E-box rich region in the regulatory region of the Foxp3.
To study whether binding of E2A to the Foxp3 promoter has a causative role in Foxp3 transcription, we challenged the ability of TGF-β1 to activate Foxp3 transcription after decreasing E2A expression. We first did gene-knockdown experiments in EL4 mouse T lymphoma cells (subclone EL4 LAF), as treatment with TGF-β1 and stimulation of the TCR induces Foxp3 expression in these cells 15, 35 . Using short hairpin RNA, we knocked down E2A expression ( Fig. 4a , inset). The presence of less E2A protein in EL4 LAF cells blocked the induction of Foxp3 expression by TGF-β1 ( Fig. 4a) . To confirm the finding that E2A binding had an intrinsic effect on Foxp3 transcription, we used a reporter Foxp3 construct containing the Foxp3 proximal promoter and the Smad enhancer (which responds to TGF-β1 directly 15 ) to engineer mutated E-boxes ( Fig. 4b, left ) and challenged the ability of TGF-β1 to activate Foxp3 promoter activity. Mutation of the sequences of the E-boxes diminished activation of the Foxp3 promoter in response to treatment with TGF-β1 and stimulation of the TCR (Fig. 4b, right ). Furthermore, we obtained naive CD4 + CD25 − T cells from E2a f/f Heb f/f Er-Cre + mice, which have tamoxifen-induced conditional deletion of loxP-flanked alleles encoding E2A (Tcf3; called 'E2a' here) and the transcription factor HEB (Tcf12; called 'Heb' here), mediated by Cre A r t i c l e s driven by the promoter of the estrogen receptor gene (Esr1; called 'Er' here), and assessed Foxp3 induction with CD3-and CD28-specific antibodies plus TGF-β1 (ref. 36 ; (Supplementary Fig. 6d,e ). We used these doubly deficient mice because they largely eliminated the possible compensatory effect of HEB in mice with conditional single deletion of E2A alone, and mice with T cell-specific double deficiency in E2A and HEB could not be used as they had an almost complete deficiency in CD4 + T cells, including T reg cells 37 . T cells with double deficiency in E2A and HEB induced by tamoxifen generated significantly fewer Foxp3 + T reg cells than did control T cells without tamoxifen induction (Fig. 4c,d) . The defect in Foxp3 induction was most profound at a low concentration of TGF-β1 (0.2 ng/ml; Fig.  4c,d) . Furthermore, we knocked down E2A with small interfering RNA (siRNA) in wild-type primary naive CD4 + CD25 − cells and found that less E2A resulted in defective Foxp3 induction in response to TGF-β1 ( Fig. 4e) . Thus, our findings show that binding of E2A to the Foxp3 promoter represents a key (enhancer) step in directly turning on Foxp3 transcription in naive CD4 + T cells in response to TGF-β1. We then examined binding of E2A to the Foxp3 promoter in Id3 −/− CD4 + CD25 − T cell populations, which showed much lower frequencies of Foxp3 + T reg cells in response to treatment with TGF-β1 (Fig. 2) . The Id3 −/− CD4 + CD25 − T cells had slightly but reproducibly more basal binding of E2A to the Foxp3 promoter in response to TCR stimulation alone than did wild-type control T cells (data not shown and presented below), which could indicate an inhibitory function for Id3 in the binding of E2A to E boxes on target genes 24 . However, TGF-β1 treatment failed to enhance the binding of E2A to the Foxp3 promoter in Id3 −/− T cells over the cells treated with stimulation of the TCR alone (Fig. 4f) . Freshly isolated CD4 + CD25 + T reg cells from the spleens of Id3 −/− mice showed no substantial enrichment of E2A at the Foxp3 promoter relative to that of CD4 + CD25 − T cells from the same mice ( Supplementary  Fig. 6c ). These data were consistent with a positive function for the binding of E-protein to E-boxes at the Foxp3 promoter but raised the question of why treatment with TGF-β1 failed to upregulate the binding of E2A to the Foxp3 promoter and consequent lack of Foxp3 expression in the Id3 −/− T cells.
A role for Id3 in regulating GATA-3 expression
We reasoned that in addition to enhancing positive regulators of Foxp3 transcription (binding of E2A to the promoter), TGF-β1 must also act to remove a negative regulator that represses Foxp3 transcription, and we hypothesized that this would require Id3. We focused on GATA-3, a key transcription factor for T helper type 2 (T H 2) differentiation 38 , reported to bind directly to the Foxp3 promoter and inhibit its transcription 39 . As TGF-β inhibits Gata3 expression in CD4 + T cells 39, 40 , we first compared Gata3 expression in Id3 −/− and wildtype CD4 + CD25 − T cells. Although naive CD4 + T cells isolated from wild-type and Id3 −/− mice had undetectable Gata3 (data not shown), Id3 −/− T cells had much more Gata3 mRNA ( Fig. 5a ) and GATA-3 protein (Fig. 5b) after TCR stimulation than did wild-type T cells. Notably, whereas it almost completely eliminated Gata3 expression in the control T cells, TGF-β1 only partially inhibited Gata3 expression in Id3 −/− T cells (Fig. 5a,b) . The higher Gata3 expression in Id3 −/− T cells was probably attributable to abundant production of IL-4 in these T cells after TCR stimulation ( Fig. 5c and data not shown) . TGF-β1 failed to substantially inhibit IL-4 expression in Id3 −/− T cells (Fig. 5c) . Although TGF-β1 suppressed Gata3 expression in Id3 −/− T cells, the overall larger amount of GATA-3 in Id3 −/− cells meant that TGF-β was unable to completely suppress GATA-3 to the amount in wild-type cells (Fig. 5a,b) . To confirm that TGF-β1 signaling had an essential role in the suppression of Gata3, we examined its expression in Tgfbr1 f/f Cd4-Cre + T cells. These cells had more GATA-3 than did control Tgfbr1 f/+ Cd4-Cre + T cells after TCR stimulation (Fig. 5d) . In Tgfbr1 f/f Cd4-Cre + T cells, the addition of TGF-β1 had no inhibitory effect on GATA-3 expression and there was no Foxp3 induction 12 (Fig. 5d) . Thus, Id3 is required for the regulation of Gata3 in CD4 + T cells, which occurs mainly through control of IL-4 production.
To understand how Id3 regulates IL-4 production in wild-type CD4 + T cells, we hypothesized that Id3 forms a complex with E2A and prevents it from binding to the E-boxes at the promoter of Il4. Indeed Il4 contains at least four E-boxes in a highly conserved region of its promoter (400 base pairs upstream of the transcription start site). We found that knockdown of E2A with siRNA in wild-type CD4 + CD25 − T cells resulted in significantly less Il4 induction in response to TCR stimulation (Fig. 5e) . These data suggest that the 'extra' E2A in the absence of Id3 could induce large amounts of IL-4 that in turn drive GATA-3 expression.
Next we assessed whether Id3 deficiency affected the binding of GATA-3 to the Foxp3 promoter. Consistent with the inhibition of Gata3 expression ( Fig. 5a,b) , treatment with TGF-β1 resulted in less binding of GATA-3 to the Foxp3 promoter in wild-type CD4 + T cells, as determined by ChIP-coupled quantitative PCR (Fig. 5f) . In line with the higher Gata3 expression in Id3 −/− T cells (Fig. 5a,b) , there was much more binding of GATA-3 to the Foxp3 promoter after TCR stimulation in these cells than in wild-type cells (Fig. 5f) . However, treatment with TGF-β1 did not diminish the binding of GATA-3 in Id3 −/− T cells to the amount in wild-type cells (Fig. 5f) . These data suggest that failure to remove GATA-3 from the Foxp3 promoter acted as a 'brake' (silencer) on Foxp3 expression. In the absence of Id3, this 'brake' rendered TGF-β1 unable to mediate the enrichment of E2A at the Foxp3 promoter, resulting in lack of Foxp3 transcription in Id3 −/− T cells.
To confirm that hypothesis, we eliminated GATA-3 from TGF-β1treated Id3 −/− CD4 + T cells by administrating an IL-4-neutralizing antibody. We had already found that naive Id3 −/− CD4 + CD25 − T cells produced large amounts of IL-4 immediately after TCR stimulation ( Fig. 5c ) and that IL-4 is a potent GATA-3 inducer 41 . Indeed, neutralization of IL-4 in TGF-β1-treated Id3 −/− CD4 + T cells abrogated their GATA-3 expression ( Fig. 5a,b ) and permitted the generation of Foxp3 + T reg cells ( Fig. 5b and Supplementary Fig. 7) . Consistent with a positive role for E2A binding in Foxp3 transcription, neutralization of IL-4 in the presence of TGF-β1 restored the enrichment of E2A at the Foxp3 promoter in Id3 −/− CD4 + T cells (Fig. 5g) . However, inhibiting only GATA-3 in the absence of TGF-β1 did not result in any generation of Foxp3 + T reg cells from either Id3 −/− or wild-type CD4 + T cells (Fig. 5b) , which suggested that downregulation of GATA-3 is only one element of the complex TGF-β1-mediated program of Foxp3 induction. That idea was further supported by the finding that elimination of GATA-3 via IL-4 neutralization in the presence of TGF-β1 did not result in Foxp3 induction in Tgfbr1 f/f Cd4-Cre + T cells (Fig. 5d) . In contrast to neutralization of IL-4, neutralization of IL-6, IL-23 or interferon-γ (IFN-γ) in TGF-β1-treated Id3 −/− CD4 + CD25 − T cells failed to restore the generation of Foxp3 + T reg cells ( Supplementary  Fig. 7 and data not shown), which eliminated the possibility that signals mediated by these cytokines served as regulators in this process. Thus, our data showed that TGF-β1 induced Foxp3 expression through at least two indispensable and interdependent molecular events: promoting binding of E2A protein to the Foxp3 promoter (enhancer), and inhibiting and/or removing negative factors bound to that promoter, such as GATA-3 (silencer). Both of these events were defective in Id3 −/− T cells.
A r t i c l e s

More T H 17 cells after deletion of Id3
As the Id3 −/− T cells showed a defect in generating CD4 + Foxp3 + T reg cells, and evidence indicates reciprocal control of T reg and T H 17 differentiation by TGF-β1 (refs. 18, 22) and that Foxp3 directly binds to and inhibits the expression of the transcription factor RORγt (encoded by Rorc) 22 , we investigated the possible dysregulation of T H 17 differentiation of Id3 −/− T cells. We first examined the frequency of T H 17 cells in the gut of Id3 −/− mice, as T H 17 cells can be detected in normal unmanipulated mice 19 . Id3 −/− mice had a much greater frequency and absolute number of T H 17 cells in the lamina propia and Peyer's patches and among intraepithelial lymphocytes than did wild-type mice (Fig. 6a,b and data not shown). In addition, the amount of IL-17 per cell was also greater in Id3 −/− T H 17 cells than in wild-type T H 17 cells (Fig. 6a, right) . T H 17 cells were almost undetectable in the spleen and peripheral lymph nodes of young and asymptomatic Id3 −/− mice, as in wild-type mice, but they were much more abundant in older Id3 −/− mice (>6 months) than in age-matched wild-type mice (data not shown). These data suggest that loss of Id3 in mice leads to more T H 17 cells.
To test whether Id3 is involved in T H 17 differentiation, we cultured naive CD4 + CD25 − T cells with TGF-β1 alone or with TGF-β1 plus IL-6 (refs. 18, 21, 22) . Treatment with TGF-β1 plus stimulation of the TCR resulted in significantly more IL-17-producing cells among Id3 −/− CD4 + CD25 − T cells but not among wild-type naive CD4 + CD25 − T cells ( Fig. 6c-e ). The addition of IL-6 to TGF-β1-treated cultures failed to further enhance the abundance of T H 17 cells in Id3 −/− T cells but substantially increased the abundance of IL-17 + cells in wild-type cultures 18, [20] [21] [22] (Fig. 6c,d) . Consistent with the effect on IL-17 production, treatment with TGF-β1 plus stimulation of the TCR induced optimal expression of Rorc in Id3 −/− T cells, and the addition of IL-6 provided no substantial enhancement (Fig. 6f) . In line with those results, neutralization of endogenous IL-6, IL-21 or IL-23 alone or in combination had no effect on the TGF-β1-induced T H 17 differentiation of Id3 −/− CD4 + CD25 − T cells (data not shown); however, neutralization of IL-4 abrogated the T H 17 polarization of Id3 −/− T cells induced by TGF-β1 ( Fig. 6e) , possibly because Foxp3 expression had been restored ( Fig. 5b and Supplementary Fig. 7b) .
We next investigated whether binding of E2A to the Rorc promoter would directly enhance transcription and IL-17 production in wildtype naive CD4 + T cells. There are four E-boxes in the promoter of Rorc 42, 43 , and binding of E-proteins to these is required for Rorc transcription in immature thymocytes during maturation 43 . We first determined that in wild-type CD4 + CD25 − T cells, treatment with TGF-β1 substantially enriched E2A at the Rorc promoter relative A r t i c l e s to TCR stimulation alone ( Supplementary  Fig. 8a) . We knocked down E2A expression in wild-type CD4 + CD25 − T cells with siRNA and showed that less E2A resulted in much less Rorc transcription and IL-17 production in the CD4 + T cells in response to TGF-β1 plus IL-6 ( Supplementary  Fig. 8b,c) . These data suggest that E2A, in combination with asyet-undetermined transcription factors downstream of IL-6, has a role in Rorc activation and the consequent T H 17 differentiation of normal T cells. In addition to the in vitro studies reported above, we also determined that naive Id3 −/− CD4 + T cells preferentially differentiated into IL-17 + cells after transfer into syngeneic Rag1 −/− mice ( Supplementary  Fig. 8d) . Although the frequency of Foxp3 + T cells was also greater among the transplanted Id3 −/− T cells than among wild-type T cells, the degree of increase in Foxp3 + T reg cells was much less than that of T H 17 cells. Thus, the ratio of T H 17 cells to Foxp3 + T reg cells was much greater for Id3 −/− T cells (Supplementary Fig. 8d ). Together our data demonstrate that in the absence of Id3, CD4 + T cells preferentially differentiated into T H 17 cells.
Id3 regulates T reg and T H 17 cells in HDM-induced asthma
We next examined whether the preferential differentiation of Id3 −/− cells into T H 17 cells might also occur during the course of disease in Id3 −/− mice. We chose a model of HDM-induced allergic asthmatic inflammation in the lung characterized by dominant T H 2 cytokines 9 . Although IL-17 has been found in experimental and human allergy and asthma, the exact function of T H 17 cells in the pathogenesis and development of asthmatic lung inflammation is under debate 44, 45 . We found that although control mice developed massive inflammatory cell infiltrates in the lung with mucus obstruction of the airways 9 , Id3 −/− mice showed considerably less infiltration of inflammatory cells and less mucus production in the airways (Fig. 7a) . Their bronchioalveolar lavage (BAL) fluid had significantly fewer inflammatory leukocytes, particularly eosinophils (Fig. 7b) . In accordance with the diminished inflammation in their lungs, Id3 −/− mice had much less immunoglobulin E (IgE) in the BAL washes ( Fig. 7c) and in the circulation (Fig. 7d) than did wild-type mice. There was a significantly greater frequency of T H 17 cells among CD4 + T cells isolated from the BAL fluid of Id3 −/− mice than among those from the BAL fluid of wildtype mice (Fig. 7e,f) , whereas their CD4 + IFN-γ + T cells were similar (Fig. 7g,h) . There were considerably fewer IL-13 + cells (Fig. 7e,f) and IL-4 + cells (Fig. 7g,h) among CD4 + T cells in Id3 −/− BAL fluid than in wild-type BAL fluid. Analysis of IL-4 protein in BAL washes and plasma provided similar results (Supplementary Fig. 9 ). The BAL fluid of Id3 −/− mice had fewer CD4 + Foxp3 + T reg cells than did the BAL fluid of wild-type mice (Fig. 7i,j) . The mediastinal draining lymph nodes and spleens of Id3 −/− mice also similarly had more T H 17 cells and fewer IL-13 + and IL-4 + T cells (Supplementary Fig. 10) , whereas CD4 + Foxp3 + T reg cells were unchanged or greater in abundance in the same tissues of Id3 −/− mice (Supplementary Fig. 10) . Nevertheless, the overall ratio of T H 17 cells to Foxp3 + T reg cells was considerably higher in Id3 −/− mice than in wild-type mice. As a control for HDMinduced lung inflammation, we also examined T cells in untreated Id3 −/− lungs. Unmanipulated Id3 −/− mice had many more IL-17 cells in the BAL fluid than did naive wild-type mice (Supplementary Fig. 11) . The BAL fluid of naive wild-type mice CD4 + T cells showed a high frequency of IL-17 + cells (~18%; Supplementary Fig. 11 ), greater than that of wild-type mice with HDM-induced asthma (Fig. 7e) . The BAL fluid of Id3 −/− mice had only slightly more IFN-γ + or IL-4 + cells than did wild-type BAL fluid but had almost undetectable IL-13 + CD4 + T cells (Supplementary Fig. 11) . Notably, the BAL fluid of untreated Id3 −/− mice contained considerably fewer CD4 + Foxp3 + T reg cells than did that of wild-type mice (Supplementary Fig. 11) . Thus, our data demonstrated that Id3 also regulated the reciprocal differentiation of T reg cells and T H 17 cells in vivo in naive lungs as well as in response to an allergic allergen in experimental asthma. On the basis of the data we have presented here, we propose a model in which the delicate balance of converging enhancer and silencer effects at the Foxp3 promoter results in correct Foxp3 transcription. Id3 has a critical role in the regulation of this process (Supplementary Fig. 12 ).
DISCUSSION
We have shown here that Id3 is critical for promoting the generation of Foxp3 + T reg cells and controlling T H 17 differentiation. A null mutation in Id3 led to a considerable deficit in CD4 + Foxp3 + T reg cells in mice.
This T reg cell deficiency occurred in both the spleen and thymus in young Id3 −/− mice, although the effect was more profound and consistent in the former organ than in the latter. We found that the defective generation of Foxp3 + T reg cell in Id3 −/− mice was T cell intrinsic, as there were fewer Foxp3 + T reg cells among CD4 + T cells in chimeras reconstituted with Id3 −/− bone marrow than in wild-type controls. We excluded the possibilities of more cell death and less population expansion as causes of the T reg cell deficiency in young Id3 −/− mice, because Id3 −/− T reg cells did not undergo more apoptosis (data not shown) and had higher rates of proliferation in vivo. Greater population expansion of T reg cells in the absence of Id3 was responsible for the higher frequency of Foxp3 + T cells in older Id3 −/− mice. Although details of the mechanisms remain to be elucidated, the inflammation and autoimmune-like disease in older Id3 −/− mice can be attributed to at least two possibilities. First, the initial deficiency in Foxp3 + T reg cells in the neonatal Id3 −/− mice resulted in lack of regulation of T cell activation. Alternatively, but not a mutually exclusively possibility, the defective suppressive function of Id3 −/− T reg cells could explain how an inflammatory syndrome was accompanied by a greater frequency of T reg cells in older Id3 −/− mice.
Notably, we have determined that Id3 has a crucial role in the correct execution of TGF-β1-mediated signals in T cells. Downstream of the TGF-β1 signal, we found that more binding of E2A had a key role in the activation of Foxp3 transcription, which was defective in Id3 −/− T cells. This enrichment of E2A was mediated by the E-boxes detected in the regulatory region of the Foxp3. This is in agreement with published findings showing that this same region (+1 kb relative to the transcription start site) corresponds to an open chromatin status (trimethylated histone H3 Lys4) in a Foxp3 gene that is being transcribed 46 . Our results showed that after treatment with TGF-β1, TBP bound to the Foxp3 promoter at the same time as E2A, which further suggested a positive role for E2A in the transcriptional regulation of Foxp3. This activity was regulated through TGF-β1 signaling; regardless of the method used to disrupt the binding of E2A to the Foxp3 promoter, disruption impaired the ability of TGF-β1 to activate Foxp3.
Our data suggest that TGF-β1 mediates enrichment of E2A at the Foxp3 promoter and that this is important in the activation of T cells at 12-24 h, which suggested potential release of E2A protein from Id3-E2A complexes, with E2A being able to bind to E-boxes at the Foxp3 promoter. Additionally, proof that TGF-β1-mediated suppression of Gata3 has a direct effect on the enrichment of E2A at the Foxp3 promoter also remains elusive, although inhibition of Gata3 could restore the E2A enrichment in response to TGF-β1 in Id3 −/− T cells. Notably, E2a-mutation experiments suggested that TGF-β1 enhances the amount of E2A bound to the Foxp3 promoter rather than changing the functional capacity of E2A. Finally, TGF-β1 could influence Foxp3 epigenetically by loosening the chromatin, allowing more access of E2A to the Foxp3 promoter. The E-proteins have been shown to form complexes with the acetyltransferases p300 and CBP and to recruit histone acetyltransferases and RNA polymerase II (ref. 26) , which may consequently promote Foxp3 transcription 47 .
Thus, details of the mechanisms by which E2A binds to E-boxes at Foxp3 promoter and how this promotes Foxp3 transcription await further investigation.
We have further demonstrated that defective TGF-β1-mediated enrichment of E2A at the Foxp3 promoter in Id3 −/− T cells was mainly due to large amounts of GATA-3 in these cells. In Id3 −/− cells, uncontrolled IL-4 production promoted the expression of GATA-3, which occupied the Foxp3 promoter and was not sufficiently suppressed by TGF-β1; thus, enrichment of E2A at the Foxp3 promoter was not possible. In support of that, neutralization of IL-4 in TGF-β-treated Id3 −/− T cells completely blocked Gata3 expression and restored the binding of E2A to the Foxp3 promoter. This consequently allowed the generation of Foxp3 + T reg cells.
To further address the issues noted above, we attempted to knock down GATA-3 with siRNA in naive T cells. However, GATA-3 knockdown proved difficult in Id3 −/− T cells (a decrease of only 20-30%) but was easier in wild-type T cells (a decrease of 80-90%). Consequently, Id3 −/− T cells treated with GATA-3-specific siRNA had only slightly more TGF-β1-mediated induction of Foxp3 (data not shown). These data further support the idea that overexpression of GATA-3 was a key factor in defective Foxp3 induction in Id3 −/− T cells. One possible reason for the insufficient knockdown of GATA-3 by siRNA was uncontrolled IL-4 production in Id3 −/− CD4 + T cells; this would antagonize the GATA-3-specific siRNA by continuously inducing more GATA-3. How Id3 deficiency leads to uncontrolled IL-4 production in T cells remains an open issue. Here we found that E2A had an important role in switching on Il4 in wild-type CD4 + T cells after TCR stimulation, which indicates a function for Id3 in inhibiting the binding of E2A to the Il4 promoter.
On the basis of the data presented here, we propose that TGF-β1 induces Foxp3 expression via at least two indispensable and complementary molecular events: by promoting the binding of E-proteins to the Foxp3 promoter (enhancer), and by inhibiting and/or removing negative factors such as GATA-3 bound to the Foxp3 promoter (silencer). Although it is too simplistic to state that E2A and GATA-3 are the only enhancer and silencer in Foxp3 gene transcription, our findings provide an example of dynamic balance between positive and negative factors as the key to correct gene transcription.
The inability of CD4 + T cells lacking Id3 to induce Foxp3 resulted in an intrinsic preference for T H 17 differentiation, as restoration of Foxp3 in Id3 −/− T cells abrogated their IL-17 production, consistent with the finding that Foxp3 interacts with Rorc and suppresses its expression 22 . In addition, we have shown that binding of E2A to the Rorc promoter may have directly enhanced its transcription and the consequent production of IL-17 in CD4 + T cells. Evidence in support of that conclusion included the following: TGF-β-enrichment of E2A at the Rorc promoter in wild-type T cells in which the TCR was stimulated, and less Rorc transcription and IL-17 production in response to TGF-β and IL-6 after siRNA-mediated knockdown of E2A. Key issues that remain are how IL-6 signals crosstalk with TGF-β-mediated E2A enrichment to promote Rorc transcription, as well as identification of the missing link in this process. In contrast to the Foxp3 promoter, the Rorc promoter contains no GATA-3-binding sites. Nevertheless, these findings provide clues to help decipher the mystery of T H 17 differentiation.
The demonstration that deletion of Id3 enhanced T H 17 cells in an asthma model highlights a function for Id3 in the balance between T reg and T H 17 differentiation in vivo. Notably, this preferential increase in T H 17 cells was not limited to allergic inflammation in Id3 −/− mice. It has also been observed in a model of experimental autoimmune encephalomyelitis (data not shown), which suggests generality of the role of Id3 in the reciprocal differentiation of T H 17 cells and T reg cells. However, the findings of more IL-17 + cells and less-abundant T H 2 cytokines, as well as less allergic inflammation in Id3 −/− mice, were unexpected, especially given that Id3 −/− T cells produced large amounts of IL-4 in vitro and in naive Id3 −/− lungs.
The mechanisms that underlie the finding of a lower abundance of T H 2 cytokines remain undefined, but our data could suggest a critical role for HDM treatment in Id3 −/− mice. BAL fluid from naive Id3 −/− mice had a greater frequency of T H 17 cells than did BAL fluid from naive wild-type mice. HDM challenge resulted in fewer T H 17 cells and more T H 2 cells in the BAL fluid of wild-type mice but even more T H 17 cells and fewer T H 2 cells in the BAL fluid of Id3 −/− mice. Thus, it remains possible that T H 17 cells may inhibit T H 2 differentiation in asthmatic inflammation. Nevertheless, our data indicate at least a lack of a positive correlation between T H 17 cells and lung inflammation in asthma, consistent with published observations 44 . However, this does not necessarily eliminate the possibility that T H 17 cells have a role in initiating the disease 45 . Collectively, our data have shown that Id3 is not only a key regulator of TGF-β-dependent immune responses, able to promote Foxp3 induction and inhibit T H 17 differentiation, but also a crucial factor in diseases that involve immune dysregulation.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
Note: Supplementary information is available on the Nature Immunology website.
